More than 90% of human myxoid liposarcoma (MLS) cases are associated with the chromosomal translocation, which creates a chimeric oncogene comprising part of the *TLS* (*translocated in liposarcoma*) gene (also known as *FUS* (*fused in Ewing\'s sarcoma*)) and part of the *CHOP* (*CCAAT/enhancer binding protein* (*C/EBP*) *homologous protein*) gene (also called *DDIT3* (*DNA damage-inducible transcript 3*) and *GADD153* (*growth arrest- and DNA damage-inducible gene 153*)) ([@bib2]; [@bib13]; [@bib12]). The resultant fusion gene *TLS--CHOP* encodes the N-terminal half of TLS fused to complete sequence of CHOP ([@bib12]; [Figure 1A](#fig1){ref-type="fig"}). TLS-CHOP protein is considered to function as an abnormal transcription factor ([@bib5]; [@bib11]; [@bib1]). The definitive TLS--CHOP function for MLS development, however, is unclear.

Melanoma differentiation-associated gene 7 (MDA-7)/interleukin-24 (IL-24) protein is expressed in cells of the immune system and normal human melanocytes ([@bib4]; [@bib15]). Exogenous expression of MDA-7/IL-24 induces growth arrest and apoptotic cell death in various human malignant cells ([@bib3]; [@bib14]).

In this report, we have found a novel pathway of TLS--CHOP with MDA-7/IL-24 repression.

Materials and methods
=====================

Cell culture
------------

The MLS-derived cell lines, 1955/91 and 2645/94, were kindly provided from Professor David Ron (University of Cambridge), and were cultured in Dulbecco\'s modified Eagle\'s medium (Sigma-Aldrich Corporation, St Louis, MO, USA) supplemented with 10% foetal bovine serum. Cell quantification was performed as previously described ([@bib8]).

Small interfering RNA transfection
----------------------------------

Small interfering RNA (siRNA) transfection (1 *μ*ℳ final concentration) was performed as previously described ([@bib8]). The nucleotide sequences of the chemically synthesised double-stranded siRNAs are as follows: *TLS--CHOP* siRNA, 5′-GGAAGUGUAUCUUCAUACAdTdT-3′ *MDA-7/IL-24* siRNA, 5′-GUGGAUGGGUGCUUAGUAAdTdT-3′ and negative control siRNA, 5′-AUCCGCGCGAUAGUACGUAdTdT-3′.

Detection of *TLS--CHOP* variants and quantitative real-time PCR analysis
-------------------------------------------------------------------------

RNA isolation and first-strand cDNA synthesis were performed as previously described ([@bib6]). For detection of *TLS--CHOP* variants, we performed PCR analysis with *TLS--CHOP* detection primers 5′-CTTATGGCCAGAGCCAGAAC-3′ and 5′-AAGGCAATGACTCAGCTGCC-3′. The amplification products were sequenced with ABI PRISM 310 Genetic analyser (Applied Biosystems, Foster City, CA, USA). Real-time PCR analysis was performed as previously described ([@bib10]) using *TLS--CHOP*-specific primers 5′-ATGAACGGCTCAAGCAGGAA-3′ and 5′-TGGTGCAGATTCACCATTCG-3′, and *MDA-7/IL-24*-specific primers 5′-GTTTTCCATCAGAGACAGTG-3′ and 5′-GTAGAATTTCTGCATCCAGG-3′. The *TLS--CHOP* and *MDA-7/IL-24* mRNA levels were normalised to *β-actin* signals ([@bib8]). We performed real-time PCR analysis in duplicate.

Microarray analysis
-------------------

Cells were transfected with the *TLS--CHOP* or negative control siRNAs, and were incubated for 72 h. Biotin-labelled complementary RNA (cRNA) was then generated from 1 *μ*g of total RNA of the cells using CodeLink iExpress Expression Assay Reagent Kit (GE Healthcare UK Ltd, Buckinghamshire, UK), and was hybridised to CodeLink Human Whole Genome Bioarray (GE Healthcare) using iAmplify cRNA Preparation and Hybridisation Reagents Kit (GE Healthcare) according to Expression Bioarray System User Guide ver. 2.0. The array slides were incubated for 21 h at 37 °C with shaking, and were scanned with a DNA microarray scanner G2505A (Agilent Technologies, Inc., Santa Clara, CA, USA). The scanned images were analysed and median normalised using CodeLink Expression Analysis Version 4.1.0.29054 (GE Healthcare). The data have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE33616.

Western blot analysis
---------------------

Western blot analysis was performed as previously described ([@bib9]). Anti-TLS--CHOP monoclonal antibody (clone 14) was previously generated ([@bib7]). Monoclonal anti-*α*-tubulin antibody clone B-5-1-2 (T-5168; Sigma) was purchased.

Plasmid construction and transfection
-------------------------------------

To create an MDA-7/IL-24 expression vector, cDNA fragment containing the complete coding region of MDA-7/IL-24 was amplified by PCR using the primers 5′-GCGCGGATCCGAGATGAATTTTCAACAGAG-3′ and 5′-GGCCAAGCTTCCTGGTCTAGACATTCAGAG-3′, and inserted into the mammalian expression vector, pcDNA3.1(−) (Invitrogen, Carlsbad, CA, USA). Plasmid transfection was performed using Lipofectamine 2000 reagent (Invitrogen) and Opti-MEM I Reduced-Serum Medium (Invitrogen).

Results
=======

TLS--CHOP knockdown represses cell growth of MLS-derived cell lines
-------------------------------------------------------------------

First, we examined the activity of the three newly designed effective siRNAs that target different positions of *TLS--CHOP* in a preliminary experiment ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), and selected the most effective siRNA among them (hereafter termed *TLS--CHOP* siRNA) for use in subsequent experiments. The *TLS--CHOP* siRNA targets exon 2 of the *CHOP* gene ([Figure 1A](#fig1){ref-type="fig"}). Although types 4 and 11 of *TLS--CHOP* variants do not have the target region, TLS--CHOP in over 80% of MLS is type 1 or 2. We confirmed that the two MLS-derived cell lines, 1955/91 and 2645/94, carries type 1 and type 2, respectively ([Figure 1B](#fig1){ref-type="fig"}). TLS-CHOP knockdown by the siRNA inhibited cell growth and induced cell death in both cell lines ([Figure 1C--F](#fig1){ref-type="fig"}). On the other hand, a non-targeting negative control siRNA did not affect cell growth, indicating that the effects of *TLS--CHOP* siRNA are not by off-target effects.

TLS--CHOP knockdown induces MDA-7/IL-24 expression in MLS cells
---------------------------------------------------------------

Next, we compared mRNA expression profiles of both 1955/91 and 2645/94 cells transfected with *TLS--CHOP* siRNA or negative control siRNA by microarray analysis (see Materials and Methods). We found that several dozen genes showed at least two-fold differential expression by *TLS--CHOP* siRNA ([Table 1](#tbl1){ref-type="table"}). Among the genes, we focused on the *MDA-7/IL-24* gene because it encodes an anticancer cytokine ([@bib3]). *TLS-CHOP* siRNA induced a significant increase in the expression of *MDA-7/IL-24* in both cell lines ([Table 1](#tbl1){ref-type="table"}; [Figure 2B](#fig2){ref-type="fig"}). Thus, to confirm that MDA-7/IL-24 is important for growth arrest by TLS--CHOP knockdown, we prepared *MDA-7/IL-24* siRNA and performed double transfection with both *TLS--CHOP* and *MDA-7/IL-24* siRNAs into 1955/91 cells. *MDA-7/IL-24* knockdown cancelled the growth inhibitory effects by *TLS--CHOP* siRNA alone ([Figure 2A and B](#fig2){ref-type="fig"}).

Overexpression of MDA-7/IL-24 represses MLS cell growth
-------------------------------------------------------

MDA-7/IL-24 displays nearly ubiquitous cancer-specific toxicity ([@bib3]; [@bib14]). To confirm that MDA-7/IL-24 is also toxic for MLS, we transfected 1955/91 and 2645/94 cells with an MDA-7/IL-24 expression vector MDA-7/IL-24-pcDNA3.1(−) or a control vector pcDNA3.1(−). As shown in [Figure 2C](#fig2){ref-type="fig"}, MDA-7/IL-24-pcDNA(3.1) transfection represses the growth of the cells.

Discussion
==========

We have demonstrated that TLS--CHOP knockdown in MLS cells represses cell growth ([Figure 1C--E](#fig1){ref-type="fig"}), suggesting that TLS--CHOP plays an essential role for growth of MLS cells. Furthermore, our results suggest that TLS--CHOP may become a promising molecular target for MLS treatment.

TLS-CHOP knockdown in MLS cells induced increased expression of an anticancer cytokine MDA-7/IL-24 ([Table 1](#tbl1){ref-type="table"}; [Figure 2B](#fig2){ref-type="fig"}). Thus, we consider that although the cancerous characteristics of MLS cells have potential to induce MDA-7/IL-24 expression, TLS--CHOP represses it and contributes to maintain the tumour growth.

In conclusion, we have revealed a novel pathway involving repression of MDA-7/IL-24 expression for tumourigenesis and/or growth of MLS. We believe that our results will contribute understanding of molecular function of the chimeric oncoprotein and development of a novel molecular therapy for cancers.
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![Repression of *TLS--CHOP* expression by *TLS--CHOP* siRNA in MLS-derived cells inhibits cell growth. (**A**) Schematic structures of various types of *TLS--CHOP* fusion gene. Grey and open boxes represent exons of the *TLS* and *CHOP* genes, respectively. The target site of *TLS--CHOP* siRNA and the hybridisation sites of *TLS--CHOP* detection primers are also shown. (**B**) Detection of *TLS--CHOP* transcripts in MLS-derived cell lines. PCR with *TLS--CHOP* detection primers was performed using cDNAs synthesised from total RNAs of MLS-derived cells. The PCR products were fractionated by electrophoresis on a 2% agarose gel. Types of *TLS--CHOP* were determined by direct sequencing of the PCR products. (**C**) Reduction of *TLS--CHOP* transcript in 1955/91 and 2645/94 cells by *TLS--CHOP* siRNA. In all, 72 h after siRNA transfection, total RNA from the cells was extracted and subjected to real-time PCR analysis. Data were normalised to a minimum mRNA level that was arbitrarily set to 1 in the graphical presentation. (**D**) Western blot analysis of total cell extracts from 1955/91 and 2645/94 cells 48 h after siRNA transfection. *α*-Tubulin is shown as a loading control. (**E**) *TLS--CHOP* siRNA inhibits cell growth of MLS-derived cells. 1955/91 and 2645/94 cells were transfected with *TLS--CHOP* siRNA or negative control siRNA. Then, the cells in 12-well culture plates were counted at several time points using a haemocytometer. *Bars*, SD. (**F**) Representative phase-contrast images of 1955/91 and 2645/94 cells at 72 h after siRNA transfection.](bjc2012199f1){#fig1}

![Growth arrest of MLS cells by *TLS--CHOP* siRNA is caused by *MDA-7/IL-24* expression. (**A**) Representative phase-contrast images (upper panels) and cell numbers (lower panel) of 1955/91 cells at 72 h after transfection with *TLS--CHOP* siRNA and/or *MDA-7/IL-24* siRNA, or negative control siRNA. (**B**) Induction of MDA-7/IL-24 expression in 1955/91 cells by *TLS--CHOP* siRNA. In all, 72 h after siRNA transfection, total RNA and protein samples were prepared from the cells and subjected to real-time PCR and western blot analysis, respectively. Left panel shows *MDA-7/IL-24* mRNA level. Data were normalised to the mRNA level of non-treated cells that was arbitrarily set to 1 in the graphical presentation. Right panel shows western blot analysis of TLS--CHOP expression. *α*-Tubulin is shown as a loading control. (**C**) Ectopic expression of MDA-7/IL-24 in MLS cells represses cell growth. 1955/91 and 2645/94 cells were transfected with expression vector. Then, the cells in 12-well culture plates were counted at several time points using a haemocytometer. *Bars*, SD.](bjc2012199f2){#fig2}

###### Differential expression probes between MLS cells treated with TLS--CHOP and negative control siRNAs

                                         **Fold change (TLS--CHOP/negative cont.)**   
  ---------- ---------- ---------------- -------------------------------------------- -------
  GE481001   C14orf34   BF573354.1       2.213                                        2.860
  GE516375   NULL       BC008580.1       11.472                                       3.080
  GE53420    GFPT2      NM_005110.1      4.367                                        2.468
  GE54247    CST7       NM_003650.2      2.708                                        2.012
  GE542691   NRG1       NM_013956.1      8.811                                        2.171
  GE57599    PI3        NM_002638.2      5.223                                        2.735
  GE57919    TNFAIP6    NM_007115.2      4.657                                        3.037
  GE58805    TXNIP      NM_006472.1      4.449                                        2.253
  GE58964    IL-24      NM_181339.1      6.112                                        2.438
  GE59353    MGLL       U67963.1         11.611                                       2.464
  GE59652    CSF3       NM_000759.2      27.532                                       4.177
  GE61078    DHRS2      NM_182908.3      2.835                                        2.566
  GE61301    C3         NM_000064.1      8.036                                        4.744
  GE616218   NULL       BC038580.2       2.768                                        2.410
  GE61968    C9orf26    NM_033439.2      3.057                                        2.141
  GE62312    PTGS2      NM_000963.1      15.187                                       3.389
  GE63376    CXCL1      NM_001511.1      6.019                                        2.180
  GE79458    HAS2       NM_005328.1      17.894                                       2.772
  GE79854    MMP3       NM_002422.2      125.188                                      4.472
  GE79985    LUM        NM_002345.3      6.591                                        2.425
  GE80239    EREG       NM_001432.1      7.313                                        2.470
  GE80932    SOD2       NM_000636.2      5.168                                        2.864
  GE833100   TNC        BQ002165.1       3.189                                        2.040
  GE854770   TMEM46     NM_001007538.1   3.332                                        2.105
  GE86887    HS3ST3B1   BC063301.1       3.554                                        2.021
  GE87032    ZIC2       NM_007129.2      2.360                                        2.952
  GE87518    ECE2       NM_032331.2      2.948                                        2.319
  GE59642    CXCL10     NM_001565.1      0.300                                        0.226
  GE59786    FBLN1      NM_006486.2      0.335                                        0.445
  GE60115    LLGL2      NM_004524.2      0.466                                        0.261
  GE80150    ELF3       NM_004433.3      0.175                                        0.424
  GE892360   NULL       BC050468.2       0.446                                        0.486

Only the probes showing over twofold change in both two cell lines are listed.

'NULL\' in Gene symbol column means that the probe sequence is not entried in NCBI database.
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